C - Chemistry – Metallurgy – 07 – K
Patent
C - Chemistry, Metallurgy
07
K
C07K 14/705 (2006.01) C12N 5/078 (2010.01) C12N 5/0783 (2010.01) A61K 38/08 (2006.01) A61K 38/17 (2006.01) A61P 35/00 (2006.01) A61P 37/04 (2006.01) C07K 7/06 (2006.01) C07K 16/28 (2006.01) C12N 15/00 (2006.01)
Patent
CA 2619443
Disclosed is a means for enabling an immunotherapy which is effective in 40% of various types of Japanese cancer patients who express a high level of Glypican-3 by identifying a GPC3-derived peptide that can bind to HLA-A2 thereby to activate a human killer T-cell. A peptide selected from the following peptides (A) and (B): (A) a peptide comprising the amino acid sequence depicted in any one of SEQ ID NOs:1-3; and (B) a peptide having the substitution or addition of one or two amino acid residues in the amino acid sequence depicted in any one of SEQ ID NOs:1-3 and capable of inducing a killer T-cell.
L'invention concerne un moyen permettant une immunothérapie, efficace dans 40 % des types variés de patients cancéreux japonais qui expriment un niveau élevé de Glypican-3, en identifiant une peptide dérivée de GPC3 pouvant se lier à l' HLA-A2, activant ainsi un lymphocyte T tueur humain. Une peptide sélectionnée à partir des peptides suivants (A) et (B) : (A) une peptide comprenant la séquence d'acides aminés décrite dans chacune des SEQ ID NO : 1-3 ; et (B) une peptide ayant un ou deux résidus d'acide aminé substitués ou ajoutés dans la séquence d'acide aminé décrite dans l'une des SEQ ID NO : 1-3 et capable d'induire un lymphocyte T tueur.
Komori Hiroyuki
Nakatsura Tetsuya
Nishimura Yasuharu
Dennison Associates
Kumamoto University
Oncotherapy Science Inc.
LandOfFree
Glypican-3 (gpc3)-derived tumor rejection antigenic peptides... does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Glypican-3 (gpc3)-derived tumor rejection antigenic peptides..., we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Glypican-3 (gpc3)-derived tumor rejection antigenic peptides... will most certainly appreciate the feedback.
Profile ID: LFCA-PAI-O-1589908